Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2551-2562

  Moser, Christian ^a   Lang, Sven A ^a   Hackl, Christina ^a   Wagner, Christine ^a   Scheiffert, Eva ^a   Schlitt, Hans J ^a   Geissler, Edward K ^a   Stoeltzing, Oliver ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; HSP90; NVP AUY922; Pancreatic cancer; Resorcinylic isoxazoles; Tumor growth

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; HEAT SHOCK PROTEIN 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MOTILITY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; PROTEIN TARGETING; WESTERN BLOTTING;

ANIMALS; CELL COMMUNICATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISOXAZOLES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; RESORCINOLS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865695718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Shaib YH, Davila JA and El-Serag HB: The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24(1): 87-94, 2006.
2. Muller MW, Friess H, Koninger J, Martin D, Wente MN, Hinz U, Ceyhan GO, Blaha P, Kleeff J and Buchler MW: Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195(2): 221-228, 2008.
3. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10): 761-772, 2005.
4. Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82(8): 488-499, 2004.
5. Xu W and Neckers L: Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13 (6): 1625-1629, 2007.
6. Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K, Sinnamon RH, Kirkpatrick RB, Kerrigan J, Lewis T, Arnone M, King AJ, Lai Z, Copeland RA and Tummino PJ: A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci 103(20): 7625-7630, 2006.
7. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956): 407-410, 2003.
8. Ogata M, Naito Z, Tanaka S, Moriyama Y and Asano G: Overexpression and localization of heat-shock protein mRNA in pancreatic carcinoma. J Nihon Med Sch 67(3): 177-185, 2000.
9. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK and Stoeltzing O: Targeting heat-shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13(21): 6459-6468, 2007.
10. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Prodromou C, Pearl C, James K, Matthews PT, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield J, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L and Workman P: NVP-AUY922: a novel heat-shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8): 2850-2860, 2008.
11. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia- Echeverria C and Chène P: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10(2): R33, 2008.
12. Kim EJ and Simeone DM: Advances in pancreatic cancer. Curr Opin Gastroenterol 27(5): 460-466, 2011.
13. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J and Fidler IJ: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16(5): 359-370, 2001.
14. Buchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Buchler MW, Lavey RS, Friess H and Hines OJ: Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 134 (5): 772-782, 2003.
15. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935): 1306-1309, 1989.
16. Gerber HP, Dixit V and Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273(21): 13313-13316, 1998.
17. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK and Cheng SY: Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162 (4): 1083-1093, 2003.
18. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N and Yamamoto H: Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79(4): 501-509, 1999.
19. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA and Law RE: Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29(1 Pt 2): 334-339, 1997.
20. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL and Ellis LM: Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163 (3): 1001-1011, 2003.
21. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK and Stoeltzing O: Inhibition of heat-shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6(3): 1123-1132, 2007.
22. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP and Ellis LM: Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulinlike growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65(17): 7775-7781, 2005.
23. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C and Stephens TC, Wallace J and Straughan DW: UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 22(3): 195-201, 1988.
24. Stingl L, Stuhmer T, Chatterjee M, Jensen MR, Flentje M and Djuzenova CS: Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 102 (11): 1578-1591, 2010.
25. Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat-shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 102 (7): 1388-1395, 2011.
26. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13(3): 565-569, 1993.
27. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N and Newcomb EW: Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196 (2): 394-402, 2003.
28. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J and Belani CP: Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13(6): 1769-1774, 2007.
29. Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, Moriwaki H and Kozawa O: HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol Rep 23(6): 1709-1714, 2010.
30. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M and Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22(13): 2610-2616, 2004.
31. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P and Judson I: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23(18): 4152-4161, 2005.
32. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S and Chayama K: Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26(4): 344-349, 2003.
33. Ghaneh P, Kawesha A, Evans JD and Neoptolemos JP: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 9(1): 1-11, 2002.
34. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R., Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-2413, 1997.
35. Kerbel RS: Tumor angiogenesis. N Engl J Med 358(19): 2039-2049, 2008.
36. Ferrara N, Heinsohn H, Walder CE, Bunting S and Thomas GR: The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 752: 246-256, 1995.
37. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF and Benjamin LE: Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2): 159-170, 2006.
38. Srinivasan R, Zabuawala T, Huang H, Zhang J, Gulati P, Fernandez S, Karlo JC, Landreth GE, Leone G and Ostrowski MC: Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One 4(12): e8283, 2009.
39. Yang X, Qiao D, Meyer K and Friedl A: Signal transducers and activators of transcription mediate fibroblast growth factorinduced vascular endothelial morphogenesis. Cancer Res 69(4): 1668-1677, 2009.
40. Zhang J, Cao R, Zhang Y, Jia T, Cao Y and Wahlberg E: Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J 23(1): 153-163, 2009.
41. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P and Eccles SA: Benzoquinone ansamycin heat-shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 5(3): 522-532, 2006.
42. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA and Giavazzi R: Antiangiogenic properties of 17-(dimethylamino-ethylamino)- 17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10(14): 4813-21, 2004.
43. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15(4): 275-286, 2004.
44. Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111(9): 1287-1295, 2003.